Mizuho Maintains Outperform on Corbus Pharmaceuticals, Raises Price Target to $44

Mizuho analyst Graig Suvannavejh maintains Corbus Pharmaceuticals (NASDAQ:CRBP) with a Outperform and raises the price target from $40 to $44.